Research
Hormonal
Advanced pharmacotherapy with GLP-1 receptor agonists can achieve 15%–20% weight loss.
Clinicians can consider GLP-1 receptor agonists as an effective pharmacotherapy option for weight loss.
StrongSupportsmedium confidence
Treatment modalities range from behavioral interventions to advanced pharmacotherapy with glucagon-like peptide-1 (GLP-1) receptor agonists, achieving 15%–20% weight loss.
Why this rating
The claim is based on a narrative review synthesizing evidence from various sources.
Source
Comprehensive Obesity Management in Clinical Practice: From Diagnostic Assessment to Evidence-Based Treatment Strategies
Vignesh Gunasekaran et al. · European Journal of Medical and Health Sciences · 2025
DOI 10.24018/ejmed.2025.7.6.2453
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →